Aberrant expression of active leukotriene C(4) synthase in CD16(+) neutrophils from patients with chronic myeloid leukemia.
Elevated leukotriene (LT)C(4) synthase activity was observed in peripheral blood granulocyte suspensions from patients with chronic myeloid leukemia (CML). Magnetic cell sorting (MACS) with CD16 monoclonal antibodies (mAbs), which were used to fractionate granulocytes from CML patients and healthy individuals, yielded highly purified suspensions of CD16(+) neutrophils. The purity of these cell fractions was verified by extensive morphologic examination. Reverse transcriptase-polymerase chain reaction (RT-PCR) analyses, demonstrating the absence of interleukin-4 messenger RNA (IL-4 mRNA), further confirmed the negligible contamination of eosinophils in these fractions. Notably, purified CML CD16(+) neutrophils from all tested patients transformed exogenous LTA(4) to LTC(4). These cells also produced LTC(4 )after activation with ionophore A23187 or the chemotactic peptide fMet-LeuPhe (N-formylmethionyl-leucyl-phenylalanine). Subcellular fractionation revealed that the enzyme activity was exclusively distributed to the microsomal fraction. Expression of LTC(4) synthase mRNA in CML CD16(+) neutrophils was confirmed by RT-PCR. Furthermore, Western blot analyses consistently demonstrated expression of LTC(4) synthase at the protein level in CML CD16(+) neutrophils, whereas expression of microsomal glutathione S-transferase 2 occurred occasionally. Expectedly, LTC(4) synthase activity or expression of the protein could not be demonstrated in CD16(+) neutrophil suspensions from any of the healthy individuals. Instead, these cells, as well as CML CD16(+) neutrophils, transformed LTA(4) to LTB(4). The results indicate that aberrant expression of LTC(4) synthase is a regular feature of morphologically mature CML CD16(+) neutrophils. This abnormality, possibly associated with malignant transformation, can lead to increased LTC(4) synthesis in vivo. Such overproduction may be of pathophysiological relevance because LTC(4 )has been demonstrated to stimulate proliferation of human bone marrow-derived myeloid progenitor cells. (Blood. 2000;95:1456-1464)
Sjölinder
M
M
Division of Physiological Chemistry II, Department of Medical Biochemistry and Biophysics, and the Division of Hematology, Department of Internal Medicine, Danderyd Hospital at Karolinska Institutet, Stockholm, Sweden.
Stenke
L
L
Näsman-Glaser
B
B
Widell
S
S
Doucet
J
J
Jakobsson
P J
PJ
Lindgren
J A
JA
D015703:Antigens, CD / Q000097:blood; D016718:Arachidonic Acid / Q000494:pharmacology; D000001:Calcimycin / Q000494:pharmacology; D005982:Glutathione Transferase / Q000097:blood* / Q000235:genetics; D006098:Granulocytes / Q000166:cytology / Q000201:enzymology / Q000473:pathology; D006801:Humans; D018189:Immunomagnetic Separation; D015847:Interleukin-4 / Q000235:genetics; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000201:enzymology* / Q000235:genetics; D015289:Leukotrienes / Q000097:blood; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000166:cytology / Q000201:enzymology* / Q000473:pathology; D012333:RNA, Messenger / Q000235:genetics; D017452:Receptors, IgG / Q000097:blood*; D013347:Subcellular Fractions / Q000201:enzymology; D014158:Transcription, Genetic
D015703:Antigens, CD; D015289:Leukotrienes; D012333:RNA, Messenger; D017452:Receptors, IgG; D015847:Interleukin-4; D016718:Arachidonic Acid; D000001:Calcimycin; D009240:N-Formylmethionine Leucyl-Phenylalanine; D005982:Glutathione Transferase; C041116:leukotriene-C4 synthase